Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer

This article was originally published in PharmAsia News

Executive Summary

Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.

You may also be interested in...



Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims

Teva has a chance to block generic competition until Sept. 1, 2015; high court declines to hear False Claims Act case against Takeda and a challenge to Allergan’s Combigan patent.

Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide

MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC086860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel